Login / Signup

Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic.

R Daniel MeyerBohdana RatitchMarcel WolbersOlga MarchenkoHui QuanDaniel LiChristine FletcherXin LiDavid WrightYue ShentuStefan EnglertWei ShenJyotirmoy DeyThomas LiuMing ZhouNorman BohidarPeng-Liang ZhaoMichael Hale
Published in: Statistics in biopharmaceutical research (2020)
Abstract-The COVID-19 pandemic has had and continues to have major impacts on planned and ongoing clinical trials. Its effects on trial data create multiple potential statistical issues. The scale of impact is unprecedented, but when viewed individually, many of the issues are well defined and feasible to address. A number of strategies and recommendations are put forward to assess and address issues related to estimands, missing data, validity and modifications of statistical analysis methods, need for additional analyses, ability to meet objectives and overall trial interpretability.
Keyphrases
  • clinical trial
  • phase ii
  • phase iii
  • study protocol
  • electronic health record
  • big data
  • open label
  • risk assessment
  • placebo controlled